Page last updated: 2024-12-07

2-deoxyglucose-6-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-Deoxyglucose-6-phosphate (2-DG-6-P) is a glucose analog that acts as a potent inhibitor of glycolysis. It is synthesized by the phosphorylation of 2-deoxyglucose (2-DG) by hexokinase, an enzyme that normally phosphorylates glucose. However, unlike glucose-6-phosphate, 2-DG-6-P cannot be further metabolized by the glycolytic pathway due to the absence of a hydroxyl group at the C-2 position. This accumulation of 2-DG-6-P effectively blocks the glycolytic pathway, leading to energy depletion and cellular stress. 2-DG-6-P has been extensively studied for its potential therapeutic applications in cancer treatment, as cancer cells often rely heavily on glycolysis for energy production. By inhibiting glycolysis, 2-DG-6-P can selectively target and kill cancer cells. Additionally, 2-DG-6-P has been investigated for its potential use in treating neurodegenerative diseases, infectious diseases, and other conditions. The compound is also a valuable tool for studying the role of glycolysis in various cellular processes. Research into 2-DG-6-P focuses on understanding its mechanisms of action, developing novel therapeutic strategies based on its properties, and exploring its potential applications in different disease settings.'

Cross-References

ID SourceID
PubMed CID108108
CHEBI ID16043
SCHEMBL ID213770
MeSH IDM0065308

Synonyms (17)

Synonym
CHEBI:16043
2-deoxyglucose 6-phosphate
3573-50-0
2-deoxy-d-arabino-hexose 6-(dihydrogen phosphate)
2-DEOXYGLUCOSE-6-PHOSPHATE ,
2-DEOXY-D-GLUCOSE-6-PHOSPHATE ,
d-arabino-hexose, 2-deoxy-, 6-(dihydrogen phosphate)
unii-zfr70wj2sl
zfr70wj2sl ,
SCHEMBL213770
Q27098347
(2r,3s,4r)-2,3,4-trihydroxy-6-oxohexyl dihydrogen phosphate
DTXSID40957140
2-deoxy-6-o-phosphonohexose
CS-0200405
HY-139409
PD007512

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The diminished uterine response is not due to a shift in the dose-response curve for E2, but results from a decrease in the magnitude of the maximum uterine response."( Regulation of the uterine response to estrogen by thyroid hormone.
Gardner, RM; Ireland, JS; Kirkland, JL; Stancel, GM, 1978
)
0.26
"In the beta-cells of the pancreas, glucose phosphorylation carried out by glucokinase is the rate-controlling step in glycolysis, and the kinetic characteristics of glucokinase govern to a high degree the dose-response relationship between glucose and insulin release."( Measurement and modeling of glucose-6-phosphatase in pancreatic islets.
Grodberg, J; Li, G; Matschinsky, FM; Najafi, H; Sweet, IR, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
deoxyaldohexose phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (122)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (44.26)18.7374
1990's49 (40.16)18.2507
2000's10 (8.20)29.6817
2010's9 (7.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.11 (24.57)
Research Supply Index4.84 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (1.60%)4.05%
Observational0 (0.00%)0.25%
Other123 (98.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]